Diazepam

CHEMBL12 Phase 4 Onaylandı Small molecule
Half-Life
20-100 hours
Bioavailability
Protein Binding
Molecular Weight
284.7 g/mol
LogP
3.0
Phase
4

Diazepam is a long-acting benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, enhancing the brain's dominant inhibitory signaling. That amplified inhibition yields anti-anxiety, sedative, anticonvulsant, and muscle-relaxant effects, and the drug is used for anxiety, alcohol withdrawal, seizures, and sedation before procedures. A small molecule (C16H13ClN2O), it is distinguished by an especially long reach: its half-life spans roughly 20 to 100 hours, extended further by active metabolites, so effects and any accumulation persist well beyond a single dose. This durability suits some indications but also raises the potential for dependence with prolonged use, as the nervous system adapts to continuous GABA enhancement. Diazepam is an approved medicine used across neurology, psychiatry, and acute care.

A long-acting benzodiazepine that enhances GABA-mediated inhibition in the brain, providing anxiolytic, sedative, anticonvulsant, and muscle-relaxant effects; used for anxiety, alcohol withdrawal, seizures, and procedural sedation. It has a risk of dependence with long-term use.

Moleküler Ağırlık

284,7400 g/mol

LogP

3,00

TPSA

32,70 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

İlaç Sınıfları

Etki Mekanizması

Positive allosteric modulator of GABA-A receptors.

Pharmacokinetics (PK)

Half-Life 20-100 hours

Pharmacodynamics (PD)

Mekanizma

Positive allosteric modulator of GABA-A receptors.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21

InChI

InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3

Molecular Formula

C16H13ClN2O

HBD / HBA

- / 2

Döndürülebilir Bağlar

1

Ağır Atomlar

20

Primary Target

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A long-acting benzodiazepine that enhances GABA-mediated inhibition in the brain, providing anxiolytic, sedative, anticonvulsant, and muscle-relaxant effects; used for anxiety, alcohol withdrawal, seizures, and procedural sedation. It has a risk of dependence with long-term use.

Positive allosteric modulator of GABA-A receptors.

Key pharmacokinetic parameters for Diazepam: Half-life: 20-100 hours.

Yes, Diazepam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL12. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3016. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.